These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 16143127)

  • 1. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
    Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
    Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
    Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
    J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMAD4 as a prognostic marker in colorectal cancer.
    Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.
    Lin YH; Friederichs J; Black MA; Mages J; Rosenberg R; Guilford PJ; Phillips V; Thompson-Fawcett M; Kasabov N; Toro T; Merrie AE; van Rij A; Yoon HS; McCall JL; Siewert JR; Holzmann B; Reeve AE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):498-507. PubMed ID: 17255271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular staging for survival prediction of colorectal cancer patients.
    Eschrich S; Yang I; Bloom G; Kwong KY; Boulware D; Cantor A; Coppola D; Kruhøffer M; Aaltonen L; Orntoft TF; Quackenbush J; Yeatman TJ
    J Clin Oncol; 2005 May; 23(15):3526-35. PubMed ID: 15908663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
    Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
    Mulder WM; Stern PL; Stukart MJ; de Windt E; Butzelaar RM; Meijer S; Adér HJ; Claessen AM; Vermorken JB; Meijer CJ; Wagstaff J; Scheper RJ; Bloemena E
    Clin Cancer Res; 1997 Nov; 3(11):1923-30. PubMed ID: 9815581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
    Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
    Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
    Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
    Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression in colorectal cancer.
    Birkenkamp-Demtroder K; Christensen LL; Olesen SH; Frederiksen CM; Laiho P; Aaltonen LA; Laurberg S; Sørensen FB; Hagemann R; ØRntoft TF
    Cancer Res; 2002 Aug; 62(15):4352-63. PubMed ID: 12154040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.
    Al-Mulla F; Hagan S; Behbehani AI; Bitar MS; George SS; Going JJ; García JJ; Scott L; Fyfe N; Murray GI; Kolch W
    J Clin Oncol; 2006 Dec; 24(36):5672-9. PubMed ID: 17179102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients.
    Bandrés E; Malumbres R; Cubedo E; Honorato B; Zarate R; Labarga A; Gabisu U; Sola JJ; García-Foncillas J
    Oncol Rep; 2007 May; 17(5):1089-94. PubMed ID: 17390049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers.
    Nakamura M; Miyamoto S; Maeda H; Zhang SC; Sangai T; Ishii G; Hasebe T; Endoh Y; Saito N; Asaka M; Ochiai A
    Clin Cancer Res; 2004 Dec; 10(24):8434-41. PubMed ID: 15623623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
    Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
    Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
    Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
    Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of gene signatures for invasive colorectal tumor cells.
    Wiese AH; Auer J; Lassmann S; Nährig J; Rosenberg R; Höfler H; Rüger R; Werner M
    Cancer Detect Prev; 2007; 31(4):282-95. PubMed ID: 17936523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.